MetLife Investment Management, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$400,464
+184.1%
21,600
+69.5%
0.00%
+200.0%
Q2 2023$140,982
-17.6%
12,7470.0%0.00%0.0%
Q1 2023$171,192
+8.6%
12,7470.0%0.00%0.0%
Q4 2022$157,680
-11.3%
12,7470.0%0.00%
-50.0%
Q3 2022$177,821
-21.8%
12,747
-22.6%
0.00%0.0%
Q2 2022$227,534
-15.1%
16,4760.0%0.00%0.0%
Q1 2022$268,065
+46.7%
16,476
+46.9%
0.00%0.0%
Q4 2021$182,692
+9.7%
11,2150.0%0.00%0.0%
Q3 2021$166,543
-25.6%
11,2150.0%0.00%0.0%
Q2 2021$223,964
-13.5%
11,2150.0%0.00%0.0%
Q1 2021$258,842
-6.6%
11,2150.0%0.00%
-33.3%
Q4 2020$277,011
-40.4%
11,2150.0%0.00%
-40.0%
Q3 2020$464,974
-13.5%
11,2150.0%0.01%
-16.7%
Q2 2020$537,311
-23.9%
11,2150.0%0.01%
-40.0%
Q1 2020$706,096
-49.2%
11,2150.0%0.01%
-28.6%
Q4 2019$1,389,763
+86.7%
11,2150.0%0.01%
+75.0%
Q3 2019$744,227
-16.6%
11,2150.0%0.01%
-20.0%
Q2 2019$892,375
-17.6%
11,215
+15.9%
0.01%
-16.7%
Q1 2019$1,082,581
+11.0%
9,6780.0%0.01%0.0%
Q4 2018$975,446
-16.3%
9,678
+4.9%
0.01%0.0%
Q3 2018$1,165,671
+36.8%
9,225
-9.1%
0.01%
+20.0%
Q2 2018$852,00010,1530.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders